- Previous Close
1.4500 - Open
1.4600 - Bid 1.4100 x 200000
- Ask 1.4900 x 220000
- Day's Range
1.4100 - 1.4850 - 52 Week Range
1.2400 - 2.2500 - Volume
9,704 - Avg. Volume
4,994 - Market Cap (intraday)
18.289M - Beta (5Y Monthly) -0.17
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 16, 2023
- 1y Target Est
--
NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, such as family planning, and preventive healthcare line products; tests for hospitals and medical practices to detect aids, Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women, including Alphabiol Beauty Elixier for the skin shine based on combination of micronutrients; Alphabiol Fertility for men; Alphabiol Curcumin Elixier mit Curcumin + Vitamin D, an essential nutrient for Vitamin D through online shops and pharmacies. The company was founded in 2006 and is headquartered in Marburg, Germany.
www.nanorepro.com22
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NN6.DE
View MorePerformance Overview: NN6.DE
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NN6.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NN6.DE
View MoreValuation Measures
Market Cap
18.29M
Enterprise Value
-12.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.04
Price/Book (mrq)
0.47
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-89.81%
Return on Assets (ttm)
-7.17%
Return on Equity (ttm)
-7.82%
Revenue (ttm)
3.56M
Net Income Avi to Common (ttm)
-3.2M
Diluted EPS (ttm)
-0.2600
Balance Sheet and Cash Flow
Total Cash (mrq)
25.8M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--